Abstract
Sarcoidosis is a chronic, systemic inflammatory disorder characterised by the presence of epithelioid non-caseating granulomata in the affected organs. The lungs are affected in about 90% of the cases, and pulmonary disease accounts for most of the morbidity and mortality associated with sarcoidosis. Virtually every organ of the body can be affected like the liver, skin, eye etc. The features of granulomata are not specific for sarcoidosis and other conditions known to cause granulomata must be excluded. These conditions include mycobacterial and fungal infections, environmental agents such as beryllium, malignancy and others.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Further Reading
Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–55.
Avasarala J. Infliximab in neurosarcoidosis. Neurology. 2017;89:2092–100.
Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–9.
Bonifazi M, et al. Pulmonary Sarcoidosis. Semin Respir Crit Care Med. 2017;38(4):437–49.
Culver DA, et al. Neurosarcoidosis. Semin Respir Crit Care Med. 2017;38(4):499–513.
Drosos AA, Constantopoulos SH, Psychos D, et al. The forgotten cause of sicca complex. J Rheumatol. 1989;16(12):1548–51.
Drosos AA, Voulgari PV, Psychos DN, et al. Sicca syndrome in patients with sarcoidosis. Rheumatol Int. 1999;18(5-6):177–80.
Joubert B, Chapelon-Abric C, Biard L, et al. Association of Prognostic Factors and Immunosuppressive Treatment with Long-term Outcomes in Neurosarcoidosis. JAMA Neurol. 2017;74(11):1336–44.
Psychos DN, Voulgari PV, Skopouli FN, Drosos AA, Moutsopoulos HM. Erythema nodosum: the underlying conditions. Clin Rheumatol. 2000;19(3):212–6.
Sayah DM, et al. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med. 2017;38(4):477–98.
West SG. Current Management of Sarcoidosis I: pulmonary, cardiac, and neurologic manifestations. Curr Opin Rheumatol. 2018;30(3):243–8.
Yee AM. Sarcoidosis: rheumatology perspective. Best Pract Res Clin Rheumatol. 2016;30(2):334–56.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pelechas, E., Kaltsonoudis, E., Voulgari, P.V., Drosos, A.A. (2019). Sarcoidosis. In: Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-03664-5_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-03664-5_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-03663-8
Online ISBN: 978-3-030-03664-5
eBook Packages: MedicineMedicine (R0)